Want to see AU:EMD full AI Analyst Report?
EMD Stock Chart & Stats
AU$0.06
>-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.06
>-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.08
Previous CloseN/A
Volume148.47K
Average Volume (3M)4.06M
Market Cap
AU$33.07M
Enterprise ValueAU$14.04M
Total Cash (Recent Filing)AU$10.50M
Total Debt (Recent Filing)AU$1.06M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,561,040
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$20.30M
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-to-equity ratio of 0.12 indicates manageable leverage and an equity‑heavy capital structure. That financial flexibility reduces solvency risk, supports access to modest additional financing, and preserves runway for clinical programs over the next several months.
Service-based Clinical & Research ModelA fee-for-service clinical model plus contracted clinical trial services provides diversified, repeatable revenue streams tied to patient care and research delivery. This operational mix supports steadier cash inflows and aligns with long-term demand for mental health and validated therapies.
Improving FCF Growth TrendA 179% free cash flow growth rate, while from a low/negative base, signals improving cash conversion dynamics. If sustained, this trend can materially reduce financing needs and lengthen runway, improving the company's ability to fund trials and clinical services over subsequent quarters.
Bears Say
Declining RevenueA 21.26% revenue decline erodes scale and undermines the economics of both clinical services and research contracts. Sustained top‑line contraction increases reliance on external funding, reduces ability to invest in trials, and heightens execution risk over the medium term.
Negative Profitability Across MarginsConsistent negative gross, EBITDA and net margins indicate structural inefficiencies or pricing shortfalls in core operations. Persistent unprofitability limits internal funding for R&D and clinical expansion, forcing tradeoffs or external capital that can dilute returns for shareholders.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows create a cash burn that pressures liquidity and requires external financing or cost cuts. This constrains investment into trials and service growth, increases dilution or leverage risk, and threatens continuity without a sustained cash improvement.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.03 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$33.07M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 56 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,561,040 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.66%
12-Months-Change
Fundamentals
Return on Equity
-52.26%
Trailing 12-Months
Asset Growth
170.82%
Trailing 12-Months
Company Description
Emyria Ltd
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Technical Analysis
Options Prices
Currently, No data available
---